durvalumab
Novel First-Line Therapy’s OS Benefit for Liver Cancer Persists
Long-term overall survival in hepatocellular carcinoma with tremelimumab plus durvalumab treatment is durable, ...
OCTOBER 27, 2023
Antibiotics Can Be Used During Durvalumab Treatment of Biliary Tract Cancer
Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based ...
JUNE 7, 2023
New Treatment for Unresectable Hepatocellular Carcinoma
The FDA has approved tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab (Imfinzi, AstraZeneca) for ...
OCTOBER 31, 2022
First Immunotherapy Regimen for Advanced Biliary Tract Cancer Approved
The FDA approved durvalumab (Imfinzi, AstraZeneca) for the treatment of adult patients with locally advanced or ...
OCTOBER 4, 2022
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 11, 2022
